Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Krish Patel, Alexey V. Danilov, John M. Pagel

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.

Original languageEnglish (US)
Pages (from-to)1573-1577
Number of pages5
Issue number19
StatePublished - 2019

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this